Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

* Have commercially manufactured brexucabtagene autoleucel that does not meet commercial release criteria but does meet Kite clinical trial release criteria

* Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential)

* Deemed medically fit and stable to receive the product per the investigator's evaluation

* Repeat leukapheresis is not feasible per the investigator's assessment

* Be diagnosed with 1 of the approved labeled indications for brexucabtagene autoleucel that is intended for release

* In the Investigator's opinion, there is no satisfactory alternative therapy available to the individual

* History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as brexucabtagene autoleucel

* Uncontrolled active infection or inflammation per physician assessment

* Primary central nervous system (CNS) lymphoma